Health
Ortho’s VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data – PRNewswire
/PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received…
RARITAN, N.J., March 23, 2021 /PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2 Antigen Test, the first high-volume SARS-CoV-2 antigen assay to receive Emergency Use Authorization (EUA) in the United States.
“Communities and laboratories across the United States continue to seek fast, reliable,…
-
Noosa News17 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General15 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
General11 hours agoPerth man charged after investigation into organised crime and tobacco store attacks
-
Business18 hours agoSolid superannuation gains continue to roll in